SI-BONE (SIBN) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to CyBone's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Saqib Iqbal, Vice President, FP and A and Investor Relations at CyBone for a few introducto ...

Artivion (AORT) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Greetings. Welcome to our Ativian's First Quarter twenty twenty five Financial Conference Call. At this time, all participants are in listen only mode. A question and answer session will follow the formal presentation. Please note that today's conference is being recorded. At this time, I'll now turn the conference over to Lane Morgan with Investor Relations. Speaker1 Lane, you may begin. Speaker2 Thanks, operator. Good afternoon, and t ...

Financial Data and Key Metrics Changes - Q1 revenue grew 18% year over year to $55.8 million, marking the thirteenth consecutive quarter of exceeding guidance [14][23] - Gross margin improved to 72.1%, a 170 basis point increase year over year [14][26] - Operating income for Q1 was $39,000, an improvement of $1.4 million year over year [28] - Adjusted EBITDA for Q1 was $1 million, improving by $1.4 million year over year [28] Business Line Data and Key Metrics Changes - Record sales in the Medical segment, particularly in MedSpa and plastic surgery, with strong performance in primary therapy [14][24] - Payments revenue continues to grow at more than twice the rate of total revenue, contributing positively to the business [25][82] - Retention metrics remained stable with Net Revenue Retention (NRR) at 98% and Gross Revenue Retention (GRR) at 91% [25] Market Data and Key Metrics Changes - The acquisition of TrueLark expands the addressable market to over $10 billion in the U.S. [7][19] - New integrations launched in Q1 increased the integrated market by approximately 60,000 locations [15] Company Strategy and Development Direction - The acquisition of TrueLark is aimed at enhancing the product roadmap and expanding market opportunities [12][20] - Focus on automating workflows and improving patient engagement through technology [8][12] - Continued investment in R&D and sales/marketing to drive growth and customer acquisition [21][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business amid economic challenges, with no degradation in lead flow or pipeline [50] - Anticipated core business growth in 2025 to outpace 2024, despite a tough year-over-year revenue comparison in Q2 [30][31] - The company remains focused on revenue growth, operational efficiency, and maintaining positive free cash flow [32] Other Important Information - The company ended Q1 with $98.2 million in cash and short-term investments, with plans to use $25 million for the TrueLark acquisition [28] - The acquisition is expected to close in Q2 2025, with performance-based equity awards tied to revenue milestones [19][21] Q&A Session Summary Question: Incremental value of TrueLark to existing bundles - Management highlighted joint customers and the revenue-driving potential of TrueLark, emphasizing its automation capabilities [36][37] Question: Specialty medical growth and hiring plans - Management confirmed strong Q1 performance in specialty medical and anticipated further growth in the back half of the year due to increased sales capacity [40][41] Question: TrueLark's pricing model and monetization opportunities - TrueLark's product is primarily sold on a per-location or per-contract basis, with opportunities for reevaluation of pricing strategies [45][46] Question: Resilience of the pipeline amid economic challenges - Management reported no degradation in pipeline metrics and expressed optimism about the integration of TrueLark enhancing their market position [49][50] Question: Competitive landscape and AI opportunity - Management noted a clear vision for their product roadmap and highlighted TrueLark's established customer base and proven ROI as competitive advantages [55][56] Question: Vertical penetration and economic sensitivity - Management indicated less than 15% penetration across all verticals, with dental being the most penetrated and specialty medical the least [68][71] Question: Customer acquisition cost and go-to-market strategy - Management confirmed ongoing efforts to refine the go-to-market strategy to reduce customer acquisition costs and increase sales velocity [75][76] Question: Payment solution attach rate - Management noted that the payment solution currently makes up less than 10% of revenue but is growing faster than overall revenue [80][81]

Syndax Pharmaceuticals (SNDX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to the Syndax First Quarter twenty twenty five Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Sharon Clary, Head of Investor Relations at Syndax Pharmaceuticals. Speaker1 Great. Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's first quarter twenty twenty five financial and operating re ...

Matson (MATX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 you for standing by and welcome to Matson's First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Justin Schoenberg, Investor Relations and Corporate Development at Matson. Please ...

EverQuote (EVER) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and thank you for standing by. My name is Calvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the EverQuote First Quarter twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. I would now like to turn the call over to Brinley ...

Financial Data and Key Metrics Changes - The company reported a total revenue growth of 18% and adjusted EBITDA growth of 32% for the first quarter [13][17] - The projects business revenue grew by 23%, while energy asset revenue increased by 31% [14][17] - The net income attributable to common shareholders was a loss of $5,500,000 or $0.10 per share [16] Business Line Data and Key Metrics Changes - The total project backlog increased by 22% to $4,900,000,000, with a contracted project backlog growing by 80% to $2,600,000,000 [17] - The energy asset operating base now stands at 742 megawatts, reflecting significant growth compared to the previous year [14] Market Data and Key Metrics Changes - The company experienced strong performance in Europe and Canada, contributing to the overall revenue growth [14] - Approximately 30% of the current total project backlog is attributed to federal government contracts, with military-related customers accounting for two-thirds [6] Company Strategy and Development Direction - The company aims to leverage federal lands for critical energy infrastructure projects, enhancing its project offerings [10] - The focus remains on diversifying energy solutions to meet the increasing demand for distributed and resilient energy systems [5][11] - The company is optimistic about capturing more infrastructure and resiliency projects as government priorities evolve [19] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the federal contracts, noting that recent cancellations have been rescoped and paused contracts have resumed [7][9] - The company anticipates continued growth in project revenue, with expectations for Q2 revenue to be in the range of $400,000,000 to $425,000,000 [18] - Management highlighted the importance of energy efficiency projects being budget-neutral, which aligns with government interests [24] Other Important Information - The company has a solid cash position of approximately $72,000,000 and total corporate debt of $270,000,000 [17] - The company is actively managing its supply chain to mitigate potential impacts from tariffs and inflation [12][41] Q&A Session Summary Question: Update on federal business visibility and contract situations - Management noted that a canceled contract has been rescoped and paused contracts have resumed, leading to a positive outlook for federal contracts [22][23] Question: Margins for Q2 and the rest of the year - Management expects gross margins for the full year to be in the range of 15.5% to 16%, despite Q1 being slightly lower due to a mix of European EPC contracts [26] Question: Impact of blackouts in Southern Europe on project opportunities - Management indicated that increasing reliance on renewable energy without adequate storage could lead to more outages, highlighting the need for distributed generation solutions [28][30] Question: Economics of projects sensitive to the Inflation Reduction Act - Management has safe harbored the ITC for many projects, minimizing short-term impacts from potential changes in the IRA [32][33] Question: Effects of reduced federal workforce on project timelines - Management has not yet seen negative impacts but acknowledged potential delays in award conversions due to administrative challenges [38][39] Question: Structure of contracts regarding tariffs - Management confirmed that new contracts include protective language against tariffs, allowing for pass-through adjustments to customers [48][50] Question: Observations on private versus public market valuations - Management noted robust private valuations for projects, despite public market fluctuations, indicating strong fundamentals in their offerings [45][46]

Castle Biosciences (CSTL) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon and welcome to Castle Biosciences First Quarter twenty twenty five Conference Call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question and answer session. I would like to turn the call over to Camilla Zuccaro, Vice President of Investor Relations and Corporate Affairs. Please go ahead. Speaker1 Thank you, operator. Good afterno ...

Offerpad Solutions (OPAD) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon, and thank you for attending today's Offerpad First Quarter twenty twenty five Earnings Conference Call. My name is Jayla, and I'll be your moderator for today. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. I'd now like to turn the conference over to our host, Courtney Reed. Courtney, you may proceed. Speaker1 Good afternoon, and wel ...

Air Lease (AL) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the Air Lease Q1 twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I will now turn the call over to Mr. Jason Arnold, Head of Investor Relations. Mr. Arnold, you may begin yo ...